Scholar Rock Holding Corporation
SRRK
Updated: 23/09/2026, 19:09:05
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
No summaries found.
- Share price
- $49.37
- Market cap
- $5.92B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- David L. Hallal
- Employees
- 289
- IPO date
- 25/05/2018
- Beta
- 0.6840000000000001
- Last dividend
- $0.00
- Day range
- $49.25 – $51.74
- 52-week range
- $27.07 – $61.76
- 1-day performance
- -3.56%
- 1-year performance
- 82.38%
- Current drawdown (1Y)
- -20.06%
- CIK
- 0001727196
- CUSIP
- 80706P103
- ISIN
- US80706P1030
- Created
- 07/12/2025, 14:23:06
- Last update
- 23/09/2026, 19:09:05
Track Scholar Rock Holding Corporation with an AI analyst
See which prediction-market events move SRRK, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Scholar Rock Holding Corporation (SRRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 09/06/2026, 14:32:14
Scholar Rock Holding Corporation (SRRK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 12/05/2026, 16:20:48
Scholar Rock Q1 Earnings Call Highlights
MarketBeat • STOCK • 09/05/2026, 00:06:20
SRRK Stock Jumps on Resubmission of FDA Filing for SMA Drug
Zacks Investment Research • STOCK • 01/04/2026, 15:40:24
Scholar Rock Holding Corporation (SRRK) Discusses BLA Resubmission for Apitegromab in Spinal Muscular Atrophy and Regulatory Progress Transcript
Seeking Alpha • STOCK • 31/03/2026, 16:22:26
Scholar Rock: From Manufacturing Hurdle To Commercial Muscle, Maintaining Buy Rating
Seeking Alpha • STOCK • 28/03/2026, 11:23:15
Scholar Rock Holding Corporation (SRRK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Seeking Alpha • STOCK • 12/03/2026, 12:52:21
Scholar Rock Holding Corporation (SRRK) Q4 2025 Earnings Call Transcript
Seeking Alpha • STOCK • 03/03/2026, 17:42:18
CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Business Wire • STOCK • 03/03/2026, 16:26:00
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%
The Motley Fool • STOCK • 22/02/2026, 13:37:02
Scholar Rock Chief Scientific Officer Conducts Multiple Sales Throughout January 2026
The Motley Fool • STOCK • 01/02/2026, 03:12:50